Former Evotec CEO Lanthaler finds home at FairJourney

Werner Lanthaler, who stepped down as CEO of Evotec SE (Xetra:EVT; NASDAQ:EVO) in early 2024, has taken the CEO role at Portuguese antibody developer FairJourney Biologics S.A. The privately held company describes itself as an “antibody partner” to other biopharmas, performing discovery and development. FairJourney founder António Parada will step away from the CEO role but retain a seat on the company’s supervisory board.

Kidney and metabolic disease company Maze Therapeutics Inc. (NASDAQ:MAZE) appointed Hervé Hoppenot as chair, replacing Charles Homcy. Hoppenot was previously chair and CEO of Incyte Corp. (NASDAQ:INCY) from 2014 to this past June, when he retired. Homcy will remain on the board...